Pheton Holdings Ltd (PTHL) Company Analysis

Company Overview

Pheton Holdings Ltd, founded in 1998 and headquartered in Beijing, China, is a healthcare solutions provider that develops and commercializes treatment software and devices used for brachytherapy. The company operates through its wholly-owned subsidiary, Beijing Feitian Zhaoye Technology Co., Ltd. Pheton’s proprietary treatment planning system employs radioactive particle implantation, a form of radiotherapy utilized in cancer treatment by placing radioactive sources inside patients to target cancer cells.

Corporate Structure

• Employee Count: Approximately 10 employees.
• Subsidiary: Beijing Feitian Zhaoye Technology Co., Ltd.
• Parent Company: ZJW (BVI) LTD.

Recent Developments

On September 5, 2024, Pheton Holdings Ltd announced the pricing of its initial public offering (IPO) of 2,250,000 Class A ordinary shares at a public offering price of $4.00 per share, aiming to raise total gross proceeds of $9 million. The shares began trading on the Nasdaq Capital Market under the ticker symbol "PTHL" on the same day. The offering is anticipated to close on September 6, 2024, subject to customary closing conditions.

Financial Performance

As of 2024, Pheton Holdings reported revenue of $448,196, a decrease of 28.70% compared to the previous year's revenue of $628,591. The company reported losses of $660,588, an increase of 173.9% from 2023.

Stock Data

• Current Price: $4.10
• Price Change: +9.04%
• Volume: 417,968
• Average Volume: 134,678
• Volume Rate: +210.35%
• Market Capitalization: Approximately $58.43 million
• 52-Week Price Range: $1.32 - $6.45

Market Position and Industry Context

Pheton Holdings operates within the healthcare sector, specifically in the medical devices industry, with a focus on brachytherapy solutions. The company’s treatment planning system, FTTPS, is designed to optimize treatment for various malignant tumors by determining target volumes and prescription doses while protecting surrounding organs.

The healthcare solutions market, especially in cancer treatment technologies, is competitive and rapidly evolving. Pheton's focus on developing treatment planning systems positions it to pursue advancements in brachytherapy.

TL;DR

Pheton Holdings Ltd (PTHL) went public on September 5, 2024, with an IPO priced at $4.00 per share, aiming to raise $9 million. The company reported revenue of $448,196 in 2024, down 28.70% from the previous year, with losses increasing to $660,588. Currently trading at $4.10, Pheton operates in the medical devices sector, focusing on brachytherapy solutions.